COMP <GO>
AAPG vs KRSA // EV/EBITDA & P/E VALUATION
Ascentage Pharma Group International American Depository Shares (NASDAQ) VS. Korsana Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: AAPG 1
— KRSA 1
■ METRIC PARITY
LAST: $14.88 (-0.70%) • MKT CAP: $1.39B
valuation
—
LAST: $30.22 (+0.37%) • MKT CAP: $1.38B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AAPG VS. KRSA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AAPG | KRSA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -5.70% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -0.24% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 3.70% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 2/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 42.1 | 45.6 | -3.50 | KRSA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.39B | $1.38B | $12.5M | AAPG | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AAPG REV | KRSA REV | AAPG GROSS % | KRSA GROSS % | AAPG FCF | KRSA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $2.1M | — | — | — | -$3.3M |
| FY 2024 | — | $2.0M | — | — | — | -$4.3M |
| FY 2023 | — | $0 | — | — | — | -$21.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AAPG // BETA —
KRSA // BETA —